D. Boral Capital Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock.

UroGen Pharma Price Performance

URGN stock opened at $10.71 on Tuesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $251.15 million, a P/E ratio of -3.40 and a beta of 1.08. The business’s 50-day moving average is $10.75 and its two-hundred day moving average is $12.21. UroGen Pharma has a 1 year low of $9.78 and a 1 year high of $20.70.

Insider Buying and Selling at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in URGN. KLP Kapitalforvaltning AS acquired a new stake in shares of UroGen Pharma during the 4th quarter worth about $59,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma during the 4th quarter worth about $67,000. Aquatic Capital Management LLC acquired a new stake in shares of UroGen Pharma during the 4th quarter worth about $101,000. China Universal Asset Management Co. Ltd. grew its stake in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after buying an additional 5,890 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.